Piper Sandler analyst Jason Bednar raised the firm’s price target on Merit Medical to $85 from $77 and keeps an Overweight rating on the shares following the Q1 beat. Most impressive from the results is the gross margin progress being shown, with Merit Medical hitting a record on this metric in Q1, the analyst tells investors in a research note. The firm continues to see the company "as a nice compounder for medtech investors."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MMSI:
- Merit Medical price target raised to $88 from $86 at Raymond James
- Merit Medical reports Q1 EPS 64c, consensus 55c
- Merit Medical Reports Results for First Quarter March 31, 2023
- Merit Medical price target raised to $84 from $78 at Needham
- Merit Medical price target raised to $86 from $80 at Raymond James